A biosimilar Filgrastim was developed and marketed by Gennova in India under the brand name Xgrast^®. The product was launched in August 2010 and is indicated for use in cancer patients receiving myelosuppressive chemotherapy, bone marrow transplant, patients with acute myeloid leukemia receiving induction or consolidation chemotherapy, patients undergoing peripheral blood progenitor cell (PBPC) collection and therapy and patients with severe chronic neutropenia.

Xgrast^® is available in different formulation as Xgrast^®-150, -300 and -480 containing Filgrastim concentrated solution Ph. Eur. Equivalent to Filgrastim 150 µg, 300 µg and 480 µg, respectively, both in vials and prefilled syringes for intravenous or subcutaneous administration, expressed in bacterial expression platform.